Kymera Therapeutics, Inc. (NASDAQ: KYMR) has announced a significant update to its partnership with Sanofi regarding the development of an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases. The new development candidate, known as KT-485/SAR447971, has been selected by Sanofi to advance into clinical studies. This decision comes after extensive preclinical work supporting its robust development potential, and KT-485 is expected to advance into phase 1 testing next year.
As a result of this decision, Sanofi will not advance KT-474, and will instead focus on KT-485. Sanofi has also communicated its decision to exercise its participation election right for the IRAK4 target under the terms of the companies’ collaboration agreement. Kymera achieved a $20 million milestone related to preclinical activities associated with KT-485 in the second quarter of 2025.
Under the collaboration agreement, Kymera is eligible to receive up to $975 million of potential clinical, regulatory, and commercial milestones related to KT-485, including an additional milestone upon the start of phase 1 clinical testing.
KT-485/SAR447971 is described as a first-in-class, selective, potent, oral IRAK4 degrader in development for the treatment of immuno-inflammatory diseases with significant patient need. It is noted that IRAK4 is a master regulator of innate immunity and a key protein of the myddosome complex that mediates signaling through IL-1 and toll-like receptors.
Kymera Therapeutics, a clinical-stage biotechnology company, has been recognized as one of Boston’s top workplaces for several years. The company is pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and has advanced the first degrader into the clinic for immunological diseases. Following these announcements, the company's shares moved 1.84%, and are now trading at a price of $47.14. For more information, read the company's full 8-K submission here.
